Medical technologies
-
Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy
Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy -
DePuy Synthes Receives FDA Clearance for TriLEAP™ Lower Extremity Anatomic Plating System
DePuy Synthes Will Bring Low-profile Plating System to Hospitals and Surgeons to Cover Forefoot, Midfoot and Hindfoot Elective and Trauma Procedures -
Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Planned interim overall survival analysis showed a trend favoring the combination of RYBREVANT® and lazertinib compared to osimertinib* First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib -
Treatment with RYBREVANT® (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Data presented at WCLC showed combining RYBREVANT ®, lazertinib and chemotherapy may address the diverse resistance that emerges after disease progression on osimertinib -
Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy
First and only AFib ablation products to receive approval for use in a workflow without fluoroscopy from the U.S. Food and Drug Administration Enables workflows with zero fluoroscopy during catheter ablation procedures Approval based on data from REAL AF Registry, demonstrating value of real-world evidence -
Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias
Industry’s highest density fixed array mapping catheter, covering the largest area in a fixed matrix format, can help physicians effectively map in a shorter procedure time -
Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc.
Separation enhances Company focus on Pharmaceutical and MedTech Research & Development to deliver innovative and differentiated health outcomes Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for shares of Kenvue Provides Johnson & Johnson shareholders with option for a tax-free exchange for U.S. Federal income tax purposes -
-
U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
TECVAYLI™, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options